Erlonat 150mg

Erlonat 150 mg is a medication that prevents the growth of tumor cells by impeding their ability to replication.
This drug is used for the treatment of metastatic or locally advanced NSCLC. Erlotinib can be used as a first-line drug for the patients, whose tumor has an EGFR. The drug can also be used after the chemotherapy (or if it has failed). The active substance of Erlonat is called Erlotinib. This ingredient detects tumor cells by their fast pace of replication, and then destroys them. In this article, you will find out more about the therapy with Erlonat.

Erlonat belongs to the group of medications called antitumor agents (they’re beneficial for the cancer therapy). Moreover, it can be used in combination with Gemcitabine for the treatment of pancreatic cancer.

Indications for use

Erlonat 150 mg can be used for the treatment of the patients with the following health conditions:

• advanced non-small cell lung cancer with an EGFR gene.
• Erlonat 150 mg can be used as their maintenance drug for the people who reacted to the previous therapies, whose disease doesn’t progress.
• Erlonat 150 mg can be used as a second-line drug for the patients with non-small cell lung cancer, whose tumor cells developed after initial therapy or chemotherapy.
• Patients undergoing initial therapy of non-small cell lung cancer, who don’t use other drugs
• People suffering from advanced pancreatic cancer can use this drug under the medical supervision.

How to use Erlonat 150 mg?

The drug comes in the form of a pill. It should be taken once a day with a full glass of water 1 hour before or 2 hours after eating. Avoid chewing the drug. Your doctor will define your daily dose. Patients with NSCLC should take 150 mg of the drug once a day. People suffering from pancreatic cancer should take 100 mg of a pill a day (together with Gemcitabine).

Nowadays, most patients with advanced lung cancer can get an efficient anti-tumor drug Erlonat, which acts by affecting certain protein (epidermal growth factor receptor, or EGFR), responsible for the immune reaction to the tumor. EFFR contributes to the growth of cancer cells. Thus, by blocking this substance, Erlonat impedes the growth and replication of cells. Before starting any treatment, you should aware about that, as the treatment of pulmonary cancer depends on the following factors –

The type of lung cancer

The stage of cancer: the size of tumor; moreover, you should find out whether the cancer affected one or two lungs
Whether the cancer has mutations in certain genes
Your general health state

Your pulmonary cancer treatment team of experienced oncologists will draw a concrete plan with you depending on your diagnosis and medical history.
Targeted therapy is a new word in the treatment of cancer. It includes medications and other substances aimed at certain molecules that contribute to the growth and replication of tumors. The idea is to affect the cancer’s unique characteristics, such as proteins, genes and host tissue. Erlotinib is a targeted medication, intended for the therapy of metastatic NSCLC and pancreatic cancer.